摘要
上皮性卵巢癌(EOC)是妇科恶性肿瘤中最致命的疾病。尽管对卵巢癌的生物学认识和疗效上都有所提高,在过去的二十年里,卵巢癌患者的生存率没有改善。由于化疗耐药性的发展,晚期患者经常复发。最近在体内和体外研究表明对这种耐药性的机制的了解,包括微核糖核酸(miRNA,miR)在耐药过程的潜在作用。在这篇综述中,我们概述了当前上皮性卵巢癌与miRNA相关的化疗耐药的治疗靶点,讨论其潜在的治疗价值和miRNA影响化疗耐药的进展和逆转的分子机制。
关键词: 卵巢癌、复发、耐药性、微核糖核酸靶点,癌基因,肿瘤抑制因子。
图形摘要
Current Cancer Drug Targets
Title:Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer
Volume: 16 Issue: 5
Author(s): Lingyun Zhang, Lubna Nadeem, Kristin Connor, Guoxiong Xu
Affiliation:
关键词: 卵巢癌、复发、耐药性、微核糖核酸靶点,癌基因,肿瘤抑制因子。
摘要: Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Despite increasing knowledge of ovarian cancer biology and advances in treatment efficacy, the survival rate of patients with EOC has not improved over the past two decades. Patients with an advanced disease often relapse due to the development of chemoresistance. Recent in vivo and in vitro studies have shown insight into the mechanisms of such drug resistance, including a potential role for microRNAs (miRNA, miR) in the process of chemoresistance. In this review, we provide an overview of current therapeutic targets of miRNA-associated chemoresistance in EOC and discuss potential therapeutic values and molecular mechanisms by which miRNAs influence the development and reversal of chemoresistance.
Export Options
About this article
Cite this article as:
Lingyun Zhang, Lubna Nadeem, Kristin Connor, Guoxiong Xu , Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009616666160404121105
DOI https://dx.doi.org/10.2174/1568009616666160404121105 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GCPII Imaging and Cancer
Current Medicinal Chemistry The Neuroprotective Effects of Purslane (Portulaca oleracea) on Rotenone- Induced Biochemical Changes and Apoptosis in Brain of Rat
CNS & Neurological Disorders - Drug Targets Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Polypharmacology of Approved Anticancer Drugs
Current Drug Targets From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Germinated Soybean Products as Nutraceutical Compounds in Breadmaking
Current Nutrition & Food Science How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Biomolecular Targets for Platinum Antitumor Drugs
Mini-Reviews in Medicinal Chemistry Molecular Insight and Binding Pattern Analysis of Shikonin as a Potential VEGFR-2 Inhibitor
Current Enzyme Inhibition Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Mini-Reviews in Medicinal Chemistry Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Nanoparticles in Gastric Cancer Management
Current Pharmaceutical Design Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets